Not Tagged
Not Tagged
[]
gi asco 2023: a new hope in refractory biliary tract cancer? positive results of nanvuranlat, an l-type amino acid transporter inhibitor. 106 patients included in this phase iii. increased pfs in all the subgroups of biliary tract cancer.
Full Prof Medical Oncology, GI Oncologist. Gustave Roussy. Paris Saclay University. Lover of sports. Tweets are my own.